Angiogenesis inhibitors: current & future directions

Area of Science:

• Focuses on the scientific principles and clinical applications of angiogenesis modulation.
• Explores the discrepancy between experimental findings and clinical outcomes in angiogenesis research.

Background:

• Basic science advancements in angiogenesis modulation are significant.
• Clinical evidence supporting angiogenesis modulation strategies remains limited.
• A gap exists between experimental data and clinical efficacy in human diseases.

Purpose of the Study:

• To highlight the critical need for human-based models in studying angiogenesis-mediated disorders.
• To emphasize the importance of clinical outcome measures, including benefit/risk, hard endpoints, and cost-effectiveness.
• To redefine the role of experimental models in guiding clinical angiogenesis research.

Main Methods:

• Utilizes human cancer patients as models for malignancy.
• Employs human patients with diabetic retinopathy (DR) and age-related macular degeneration (AMD) for ocular angiogenesis studies.
• Advocates for incorporating benefit/risk ratios, mortality, quality of life, and cost-effectiveness in clinical evaluations.

Main Results:

• Experimental models are best suited for mechanistic understanding and guidance, not predicting clinical efficacy.
• Human patient data is essential for validating angiogenesis modulation strategies.
• Numerous angiogenesis modulation strategies have been identified, targeting various biological systems.

Conclusions:

• Human patient-derived data and clinically relevant endpoints are paramount for successful angiogenesis modulation therapies.
• Experimental models should complement, not replace, human studies.
• Future strategies must integrate with existing treatments to improve efficacy and safety.